Monday, 8 April 2013

Peramavir for H7N9 and more detections confirmed...

19th and 20th cases of confirmed influenza A(H7N9)

Peramivir, a new intravenous drug, is designed to target both influenza A and B viruses. Developed by US-listed biotech BioCryst Pharmaceuticals, it has been fast-tracked by Chinese FDA. 

The US CDC developing a candidate virus seed strain.